1. Annual Report 2025
  2. Research
  3. EMAP

EMAP

Research on Drugs in Primary Care

The Primary Care Medicine Studies Group (EMAP) is a research group accredited by IDIAPJGol and AGAUR. Its main objective is to conduct excellence-driven research on the use of medicines in the field of Primary Care.
We are an interdisciplinary group with expertise in carrying out studies using diverse methodologies. The main research lines are interconnected and fall within two major areas:

- Pharmacoepidemiological and pharmacovigilance studies using large databases focused on assessing drug effectiveness and safety under real-world conditions and in understudied populations such as children, polymedicated patients, pregnancy, breastfeeding, and the elderly.

- Prospective studies involving patient inclusion, mainly clinical trials with medicines and medical devices that meet the specific needs of Primary Care, using pragmatic designs that emulate clinical practice while generating new scientific evidence and facilitating knowledge transfer to healthcare.

EMAP participates in the development of independent clinical trials through management, monitoring, and pharmacovigilance activities. In this regard, the group is part of the SCReN network (Spanish Clinical Research Network). We are also part of the SIGMA Consortium, responsible for providing scientific evidence in pharmacoepidemiology using European databases, together with research on drug use during pregnancy (ConcePTION) and pharmacovigilance of COVID-19 vaccines (VAC4EU). The group also supports the Catalan Therapeutic Harmonization Program (CatSalut) and the Catalonia Pharmacovigilance Centre through the Technical Office of Pharmacoepidemiology, studying real-world drug use. In addition, we collaborate with other networks such as Ciber, Ricapps, Ecraid and EU PE&PV Research Network.

The multidisciplinary nature of the group-comprising researchers in pharmacoepidemiology and pharmacovigilance, data managers, statisticians, pharmacologists specialized in pharmacovigilance, project managers, clinical research associates, and qualitative research specialists-enables the achievement of its objectives due to the diverse expertise of its members.

Group projects

  • Uso de fármacos en mujeres embarazadas y lactantes. Consecuencias en la salud de estas mujeres y en la de su descendencia. (SLT021/21/000068). Generalitat Catalunya. 2022-2025. IP: Cristina Vedia Urgell.

  • Safety of Paxlovid during pregnancy (C4671037, VAC4EU & SIGMA study). Pfizer, S.A.; Research Triangle Institute (RTI). 2023-2026. IP: Maria Giner Soriano.

  • Safety of Paxlovid among patients with moderate or severe hepatic or renal impairment (C4671047, VAC4EU & SIGMA study). Pfizer, S.A.; Research Triangle Institute (RTI). 2023-2026. IP: Maria Giner Soriano.

  • Riscos de les interaccions farmacològiques dels anticoagulants orals directes: esdeveniments trombòtics i hemorràgics que són motiu d'ingrés hospitalari a Catalunya. Generalitat Catalunya. 2022-2025. IP: Rosa Morros Pedrós.

  • Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries. Pfizer, S.A.; Research Triangle Institute (RTI). 2022-2025. IP: Maria Giner Soriano.

  • Post-Authorisation Safety Study of AZD1222. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources. Research Triangle Institute (RTI). 2021-2025. IP: Maria Giner Soriano.

  • Mild-moderate respiratory symptoms in patients with long-COVID-19: montelukast clinical trial and biological characterization (ESPERANZA COVID). (ICI21/00106). Instituto de Salud Carlos III. 2021-2026. IP: Rosa Morros Pedrós.

  • Hemorràgies majors en pacients tractats amb anticoagulants i interaccions farmacològiques: estudi cas-control amb dades de la història clínica d'Atenció Primària a Catalunya. 2023-2026. IP: Maria Giner Soriano.

  • Experiencias y conocimientos de pacientes y profesionales sanitarios sobre la migraña (Estudio PREMI): Estudio Cualitativo. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Maria Giner Soriano.

  • Estudi d'utilització de medicaments pel tractament de la insuficiència cardíaca. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Maria Giner Soriano.

  • Estudi descriptiu sobre la migranya. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Maria Giner Soriano.

  • Desarrollo de un modelo predictivo de falta de adherencia terapéutica en el contexto del proyecto BEAMER. 2023-2026. IP: Maria Giner Soriano.

  • Comparación de la efectividad de fármacos en primera línea de tratamiento preventivo de la migraña en Atención Primaria: ensayo clínico pragmático. Estudio PREMI. (ICI23/00047). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol); Instituto de Salud Carlos III. 2023-2026. IP: Maria Giner Soriano.

  • Validacion de b-compass en Cataluña y su relación con la adherencia al tratamiento y control de las enfermedades. Innovative Medicines Initiative (IMI); Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Rosa Morros Pedrós.

  • TARGET EU - Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks: Rivaroxaban and risk of major gastrointestinal bleeding in elderly patients with non-valvular atrial fibrillation (version 0.3, 10 November 2025). European Medicines Agency (EMA). 2025-2028. IP: Maria Giner Soriano.

  • Study protocol for the Teratogenic Drugs Prioritisation (TDP) project combining pre-clinical data with clinical data from ConcePTION data sources (task 7.9). 2024-2026. IP: Maria Giner Soriano.

  • Riesgo de caídas y caídas con fractura en pacientes de edad avanzada: estudio de casos y controles. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2026. IP: Àurea Cartanyà Hueso.

  • PRECISION-MPOC (Medicina de Precisió a MPOC Basada en Trets Tractables i severitat). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2027. IP: Rosa Morros Pedrós.

  • ORION (Ozanimod Real-World Safety - A Post-Authorisation Multinational Long-Term Non-Interventional Study). European Medicines Agency (EMA); Evidera, Inc. (GB660417353). 2025-2028. IP: Maria Giner Soriano.

  • Estudio de utilización de medicamentos para el tratamiento de la insuficiencia cardíaca (IDIAP-IC-2025). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Maria Giner Soriano.

  • Estudi d'utilització de medicaments per al tractament de la malaltia pulmonar obstructiva crònica a Catalunya. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Maria Giner Soriano.

  • Efectividad de la administración de fosfomicina trometamol monodosis versus dos dosis en mujeres con infección urinaria baja no complicada. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Rosa Morros Pedrós.

  • Association between previous biologic therapy exposure and incidence and severity of life-threating infections in patients with rheumatoid arthritis and psoriasis. A population-based cohort study. Consorcio Centro de Investigación Biomédica en RED (CIBER); Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2027. IP: Rosa Morros Pedrós.

  • Antiseizure meDication Exposure and Pregnancy and neonaTal outcomes research (ADEPT). Use of antiepileptics, and feasibility of studies on the association between maternal and paternal exposure to antiepileptics and adverse pregnancy, neonatal and child outcomes. (EMA/453898/2023). European Medicines Agency (EMA). 2024-2027. IP: Maria Giner Soriano.

  • A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data. European Medicines Agency (EMA). 2024-2026. IP: Maria Giner Soriano.

Group publications

  • Fernández Garcia S, Moragas A, Giner Soriano M, Morros R, Ouchi D, Garcia Sangenis A et al. Urinary tract infections in women in Catalonia, Spain: a population-based observational cohort study in primary care. Front. Pharmacol. 2025;161593910-1593910. PMID:40994650.

  • Munné Barellas B, Monfà R, Llor C, Garcia Sangenís A, Miranda Jiménez C, Morros R et al. The Use of Antibiotics for Uncomplicated Urinary Tract Infections in Adult Women: Qualitative Findings From the SCOUT Trial. Patient Prefer. Adherence. 2025;192673-2685. PMID:40917820.

  • Monfà R, García Sangenís A, Morros R, Sáez CMZ, Mateos Nozal J, Pinto MNV et al. The impact of a multifaceted intervention on antibiotic use for common infections in nursing homes in Spain. A before and after study. Eur. Geriatr. Med. 2025;16(4):1465-1473. PMID:40261575.

  • Domen J, Aabenhus R, Balan A, Bongard E, Böhmer F, Bralic Lang V et al. The effect of a general practitioner's perception of a patient request for antibiotics on antibiotic prescribing for respiratory tract infections: secondary analysis of a point prevalence audit survey in 18 European countries. BJGP Open. 2025;9(2): PMID:39824603.

  • Morros R, Moragas A, García Sangenís A, Monfà R, Miravitlles M, Vallejo Torres L et al. Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care: Protocol fora Pragmatic Randomized Controlled Trial Study (STORM). JMIR RES. Protoc. 2025;14PMID:41115271.

  • Bellas L, Camacho Arteaga L, Giner Soriano M, A, Gómez Lumbreras A, Aguilera C et al. Real-World Data Insights into Antidepressant Prescription and Adherence During Pregnancy in Catalonia (Spain). Drug Saf. 2025;48(12):1353-1364. PMID:40632487.

  • Toledo D, Cartanyà Hueso À, Morros R, Giner Soriano M, Domínguez À, Vilaplana Carnerero C et al. Impact of Long-Term Statin Therapy on Incidence and Severity of Community-Acquired Pneumonia: A Real-World Data Analysis. Biomedicines. 2025;13(6): PMID:40564157.

  • Theut M, Jonsson A, Jensen JN, Antsupova V, Hansen MP, Llor C et al. Factors influencing urinary tract infection prevention and antibiotic stewardship in European nursing homes: an-interview study with staff. Eur. Geriatr. Med. 2025;16(6):2293-2303. PMID:41117869.

  • Llor C, Ouchi D, Fernández García S, Giner Soriano M, Moragas A, Morros R. Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study. BMJ Open. 2025;15(8): PMID:40819861.

  • García Sangenís A, Raynal Floriano F, López Valcárcel BG, Vallejo Torres L, Llor C, HAPPY PATIENT Study G. Effect of a multifaceted intervention on potentially unnecessary antibiotic prescriptions in general practice, out-of-hours services, and nursing homes in Spain. Rev. Esp. Quim. 2025;38(3):234-239. PMID:40145525.

  • Llor C, Hansen MP, Lykkegaard J, Olsen J, Lindberg BH, Rebnord IK et al. Duration of antibiotic treatment for respiratory tract infections in primary care. JAC-Antimicrob. Resist. 2025;7(1): PMID:40008154.

  • Giner Soriano M, Ricart GA, Cartanyà Hueso A, Gomez Lumbreras A, Vázquez ML, Morros R et al. Drug exposure during breastfeeding: a descriptive population-based cohort study with SIDIAP database. Int. Breastfeed. J. 2025;21(1):7-7. PMID:41444905.

  • Giner Soriano M, Morros R, Monfà R, Ouchi D, Fernández García S, Vedia C et al. Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study). Trials. 2025;26(1):311-311. PMID:40859286.

  • Lambert M, Benko R, Lykkegaard J, Sondergaard J, Olsen J, Garcia Sangenis A et al. Community pharmacists' role in optimising antibiotic use: The HAPPY PATIENT project to improve dispensing practices in five EU countries. Res. Soc. Adm. Pharm. 2025;21(8):597-607. PMID:40204618.

  • García Egea A, García Sangenís A, Llor C, Berenguera A, Moragas A, Monfà R et al. Clinicians' perspectives on a primary healthcare intervention to reduce antibiotic prescription for acute lower respiratory tract infections in Barcelona (Spain): a qualitative study. Prim. Health Care Res. Dev. 2025;26PMID:40611657.

  • Giner Soriano M, Carrasco Ribelles LA, Fernández García S, Castel Llobet J, Cereza García G, Morros R. Association Between Anticoagulants and Interacting Drugs and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation: Case-Control Study in SIDIAP, Catalonia, Spain. Clin. Ther. 2025;47(7):484-491. PMID:40348694.

  • Llor C, Olsen J, Lykkegaard J, Anastasaki M, Jensen JN, Sondergaard J et al. Assessment of potentially unnecessary antibiotic use for suspected urinary tract infections in nursing homes using a simplified algorithm. Expert Rev. Anti-Infect. Ther. 2025;23(2-4):1-7. PMID:39831536.

  • Fernandez Garcia S, Monfa R, Jimenez CM, Giner Soriano M, Gomez F, Moragas A. Appropriateness of urine culture requests in primary care in Spain: A cross-sectional descriptive study. Aten. Prim. 2025;57(7):103208-103208. PMID:39799637.

  • Hansen MB, Lykkegaard J, Hansen MP, Llor C, Sangenis AG, Touboul Lundgren P et al. Appropriateness of antibiotic use in nursing homes for suspected urinary tract infections: comparison across five European countries (vol 16, pg 1453, 2025). Eur. Geriatr. Med. 2025;17(1):407-407. PMID:40932593.

  • Hansen MB, Lykkegaard J, Hansen MP, Llor C, Sangenis AG, Touboul Lundgren P et al. Appropriateness of antibiotic use in nursing homes for suspected urinary tract infections: comparison across five European countries. Eur. Geriatr. Med. 2025;16(4):1453-1464. PMID:40146526.

  • Giner Sorian M, Monfa R, Vives R, Fernandez Garcia S, Vallano A, Morros R. [Clinical characteristics and pharmacological treatment of patients with heart failure in a primary health care cohort]. Aten. Prim. 2025;57(7):103205-103205. PMID:39823656.

Proceeding Papers

  • Colas S, Bonnet H, Fraticelli L, Bignon E, Jové J, Ehrenstein V et al. Studying Paternal Drug Exposures and Offspring Outcomes: Feasibility Assessment of Large European Databases. Pharmacoepidemiol. Drug Saf. 2025;34154-155.

  • Colas S, Bonnet H, Fraticelli L, Bignon E, Jové J, Ehrenstein V et al. Studying paternal drug exposures and offspring outcomes: a feasibility assessment of 11 large european databases. Value health. 2025;28(12). 

  • Gomez Lumbreras A, Ouchi D, Giner Soriano M, Morros R. Risk of Hemorrhage in Patients on Oral Anticoagulants Due to Pharmacodynamic Drug Interactions: A Case-Crossover Analysis. Pharmacoepidemiol. Drug Saf. 2025;3448-49.

  • Margulis AV, de Luise C, Aguado J, Navarro C, Boric K, Campbell C et al. Preliminary Results from a European Post-Authorization Study to Assess the Safety of Paxlovid in Pregnancy. Pharmacoepidemiol. Drug Saf. 2025;34545-546.

  • Rebordosa C, de Luise C, Aguado J, Bertran S, Boric K, Campbell C et al. Preliminary Results from a European Post Authorization Study to Assess the Safety of Paxlovid among Patients with Moderate or Severe Hepatic or Renal Impairment. Pharmacoepidemiol. Drug Saf. 2025;34302-303.

  • Munné Barellas B, Monfà R, Llor C, Garcia Sangenís A, Miranda Jiménez C, Morros Pedrós R et al. Preferences in the use of antibiotics for uncomplicated urinary tract infections in adult women: a qualitative study of a clinical trial (scout). Gac. Sanit. 2025;39.

  • Glasova H, Glasa J, Llor C, Lykkegaard J, Hansen MP, Jensen JN et al. Improving antibiotic use in long-term care facilities (project IMAGINE): lessons learned from the first phase of the project implementation. Eur. J. Clin. Pharmacol. 2025;81(1):46-46.

  • Glasa J, Glasova H, Slezáková Z, Krcméryova T, Kollárová A, Fabiánová Z et al. Improving antibiotic use in long-term care facilities (project IMAGINE): a target country perspective (Slovakia). Eur. J. Clin. Pharmacol. 2025;81(1):43-43.

  • Giner Soriano M, Ricart GA, Cartanya Hueso A, Morros R, Gomez Lumbreras A, Vazquez ML et al. Frequent Drug Exposure during Breastfeeding: A Population-Based Cohort Study with SIDIAP Database. Pharmacoepidemiol. Drug Saf. 2025;34417-418.

  • Toledo D, Cartanya Hueso A, Morros R, Giner Soriano M, Domínguez A, Grau M. Effectiveness of chronic statin treatment on the incidence of community-acquired pneumonia. Gac. Sanit. 2025;39.

  • Toledo D, Cartanya Hueso A, Morros R, Giner Soriano M, Dominguez A, Grau M. Effectiveness of chronic statin treatment on the incidence and severity of influenza. Gac. Sanit. 2025;39. 

  • Giner Soriano M, Cartanyà Hueso A, Gomez Lumbreras A, Morros R, Vázquez ML, Vedia C. Association between cardiac congenital malformations and mothers' drug use during pregnancy in Catalonia, Spain. Pharmacoepidemiol. Drug Saf. 2025;34545-545.

  • Gomez Lumbreras A, Sangenis AG, Vedia C, Morros R. Antipsychotic Use in Youth and Children: A Cohort Study from Catalonia (Spain) of Treatment Patterns. Pharmacoepidemiol. Drug Saf. 2025;34485-485.

Theses

  • Barceló J(Autor). Evolució del tractament antimicrobià de la prostatitis aguda a l'atenció primària a Catalunya i impacte dels programes d'optimització d'antimicrobians en la seva tendència, Universidad Autónoma de Barcelona.

  • El suport social i sanitari durant l'embaràs i la lactància en dones i en les seves parelles o acompanyants a Catalunya: un estudi qualitatiu, Barcelona. Universidad Pompeu Fabra. 2025.

Anar a l'inici